CZ20032060A3 - Farmaceutický prostředek - Google Patents

Farmaceutický prostředek Download PDF

Info

Publication number
CZ20032060A3
CZ20032060A3 CZ20032060A CZ20032060A CZ20032060A3 CZ 20032060 A3 CZ20032060 A3 CZ 20032060A3 CZ 20032060 A CZ20032060 A CZ 20032060A CZ 20032060 A CZ20032060 A CZ 20032060A CZ 20032060 A3 CZ20032060 A3 CZ 20032060A3
Authority
CZ
Czechia
Prior art keywords
compound
nerve
injury
formula
spinal cord
Prior art date
Application number
CZ20032060A
Other languages
Czech (cs)
English (en)
Inventor
Nobuya Matsuoka
Takayuki Yamaji
Bruce Gold
Original Assignee
Fujisawa Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd filed Critical Fujisawa Pharmaceutical Co., Ltd
Publication of CZ20032060A3 publication Critical patent/CZ20032060A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Packages (AREA)
  • Saccharide Compounds (AREA)
CZ20032060A 2000-12-29 2001-12-31 Farmaceutický prostředek CZ20032060A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25850000P 2000-12-29 2000-12-29

Publications (1)

Publication Number Publication Date
CZ20032060A3 true CZ20032060A3 (cs) 2004-01-14

Family

ID=22980816

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20032060A CZ20032060A3 (cs) 2000-12-29 2001-12-31 Farmaceutický prostředek

Country Status (18)

Country Link
EP (1) EP1353671A4 (zh)
JP (1) JP2004527472A (zh)
KR (2) KR100794204B1 (zh)
CN (1) CN1293877C (zh)
AR (1) AR035411A1 (zh)
AU (1) AU2002231277B2 (zh)
BR (1) BR0116762A (zh)
CA (1) CA2433384A1 (zh)
CZ (1) CZ20032060A3 (zh)
HU (1) HUP0302521A3 (zh)
IL (1) IL156664A0 (zh)
MX (1) MXPA03005941A (zh)
NO (1) NO20032913D0 (zh)
NZ (1) NZ527209A (zh)
PL (1) PL366301A1 (zh)
RU (1) RU2288716C2 (zh)
WO (1) WO2002053159A1 (zh)
ZA (1) ZA200305806B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
JP2007518692A (ja) * 2004-01-20 2007-07-12 アステラス製薬株式会社 勃起不全治療方法
EP1810675A1 (en) * 2006-01-18 2007-07-25 Institut Curie Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421
JP2009102226A (ja) * 2006-02-14 2009-05-14 Meiji Milk Prod Co Ltd 脊髄損傷治療剤
CA2730751A1 (en) * 2008-07-23 2010-01-28 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
EP2817009A1 (en) * 2012-02-23 2014-12-31 INSERM - Institut National de la Santé et de la Recherche Médicale Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
GB201309375D0 (en) * 2013-05-24 2013-07-10 Chronos Therapeutics Ltd Medical methods and compounds for medical use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2799208B2 (ja) * 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー マクロ環状化合物
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
US5541193A (en) 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators
GB9202196D0 (en) * 1992-02-01 1992-03-18 Fisons Plc Method of treatment
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use

Also Published As

Publication number Publication date
EP1353671A1 (en) 2003-10-22
KR100794204B1 (ko) 2008-01-14
CA2433384A1 (en) 2002-07-11
NO20032913D0 (no) 2003-06-24
AR035411A1 (es) 2004-05-26
HUP0302521A3 (en) 2007-03-28
AU2002231277B2 (en) 2006-11-30
KR20070030331A (ko) 2007-03-15
CN1538843A (zh) 2004-10-20
JP2004527472A (ja) 2004-09-09
ZA200305806B (en) 2005-01-26
EP1353671A4 (en) 2004-07-14
NZ527209A (en) 2005-09-30
CN1293877C (zh) 2007-01-10
RU2288716C2 (ru) 2006-12-10
HUP0302521A2 (hu) 2003-11-28
RU2003123493A (ru) 2005-01-20
MXPA03005941A (es) 2005-02-14
KR20040007431A (ko) 2004-01-24
IL156664A0 (en) 2004-01-04
PL366301A1 (en) 2005-01-24
WO2002053159A1 (en) 2002-07-11
BR0116762A (pt) 2004-08-10

Similar Documents

Publication Publication Date Title
DE60316798T2 (de) Zusammensetzungen und verfahren zur behandlung von diabetes
KR100298808B1 (ko) 외상손상과관련된신경학적병변의치료를위한,릴루졸을포함하는제약학적조성물
CN111278440B (zh) 用普利多匹定治疗肌萎缩性脊髓侧索硬化症的方法
Mentis et al. Motoneurons destined to die are rescued by blocking N-methyl-D-aspartate receptors by MK-801
Geisler et al. GM-1 ganglioside in human spinal cord injury
HU217543B (hu) Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények
JP5243428B2 (ja) 神経細胞の損傷を減少させるための薬学的組成物
DE69635754T2 (de) Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe
CZ20032060A3 (cs) Farmaceutický prostředek
JP3623501B2 (ja) インターロイキン−１阻害化合物による神経病学的状態の治療
DE69928521T2 (de) Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit
Alvarez et al. Hippocampal histamine receptors: possible role on the mechanisms of memory in the rat, II
Wahlestedt et al. Neurogenic mechanisms in control of the rabbit iris sphincter muscle
US6284771B1 (en) Method for treating schizophrenia
US5236932A (en) Method for treating Parkinson's disease employing quinine
WO2017057562A1 (ja) 末梢神経障害又は脊髄損傷の治療剤及び／又は予防剤
AU2002231277A1 (en) Neurotrophic tacrolimus analogs
EP0147185A2 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
EP0305181B1 (en) Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin
KR100195651B1 (ko) 신경 손상 및 발작의 치료를 위한 nk-1 수용체 길항물질
JP2009504636A (ja) 血漿または血清を含む神経損傷治療用の医薬組成物
US20040077676A1 (en) Neurotrophic tacrolimus analogs
DE60215525T2 (de) Kombination aus quetiapin und zolmitriptan
CA2455896A1 (en) Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma
Schneider The therapeutic role of gangliosides in neurological disorders